Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine

被引:109
作者
Zullino, DF [1 ]
Delessert, D [1 ]
Eap, CB [1 ]
Preisig, M [1 ]
Baumann, P [1 ]
机构
[1] Univ Lausanne, Dept Adult Psychiat, Unit Biochem & Clin Psychopharmacol, Clin Cery, CH-1008 Lausanne, Switzerland
关键词
antipsychotic agents; cannabis; cytochrome P-450; enzyme induction; smoking; smoking cessation;
D O I
10.1097/00004850-200205000-00008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Plasma levels of clozapine and olanzapine are lower in smokers than in nonsmokers, which is mainly due to induction of cytochrome P4501A2 (CYP1A2) by some smoke constituents. Smoking cessation in patients treated with antipsychotic drugs that are CYP1A2 substrates may result in increased plasma levels of the drug and, consequently, in adverse drug effects. Two cases of patients who smoked tobacco and cannabis are reported. The first patient, who was receiving clozapine treatment, developed confusion after tobacco and cannabis smoking cessation, which was related to increased clozapine plasma levels. The second patient, who was receiving olanzapine treatment, showed important extrapyramidal motor symptoms after reducing his tobacco consumption. The clinical implication of these observations is that smoking patients treated with CYP1A2 substrate anti psycho tics should regularly be monitored with regard to their smoking consumption in order to adjust doses in cases of a reduction or increase in smoking. Int Clin Psychopharmacol 17:141-143 (C) 2002 Lippincott Williams Wilkins.
引用
收藏
页码:141 / 143
页数:3
相关论文
共 18 条
[1]   Smoking cessation treatment for patients with schizophrenia [J].
Addington, J ;
el-Guebaly, N ;
Campbell, W ;
Hodgins, DC ;
Addington, D .
AMERICAN JOURNAL OF PSYCHIATRY, 1998, 155 (07) :974-976
[2]   NEURAL MECHANISMS UNDERLYING NICOTINE DEPENDENCE [J].
BALFOUR, DJK .
ADDICTION, 1994, 89 (11) :1419-1423
[3]   Very nigh cytochrome P4501A2 activity and nonresponse to clozapine [J].
Bender, S .
ARCHIVES OF GENERAL PSYCHIATRY, 1998, 55 (11) :1048-1050
[4]  
Bron C, 2000, Praxis (Bern 1994), V89, P1695
[6]  
Ereshefsky L, 1996, J CLIN PSYCHIAT, V57, P12
[7]   Induction of drug metabolising enzymes - Pharmacokinetic and toxicological consequences in humans [J].
Fuhr, U .
CLINICAL PHARMACOKINETICS, 2000, 38 (06) :493-504
[8]   Neurobiology of tobacco smoking and other addictive disorders [J].
Gamberino, WC ;
Gold, MS .
PSYCHIATRIC CLINICS OF NORTH AMERICA, 1999, 22 (02) :301-+
[9]  
GLASSMAN AH, 1993, AM J PSYCHIAT, V150, P546
[10]  
HARING C, 1989, PSYCHOPHARMACOLOGY S, V99, P38